Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy

• Status: Completed
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This observational study aims to investigate how VIMPAT® is used as adjunctive therapy in clinical practice and will also evaluate the subsequent change in the drug load of patients after addition of VIMPAT® to their treatment regimen.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UCB Pharma GmbH
• Treatments: Anticonvulsants; Lacosamide

Criteria

Inclusion Criteria:

• The patient has not received Vimpat® more than 7 days prior to start of Non-Interventional Study (NIS)

• The patient must have a diagnosis of epilepsy with partial-onset seizures with or without secondary generalization

• Based on the physician's clinical judgment, it is in the patient's best interest to be prescribed adjunctive Vimpat® (ie, the decision to prescribe Vimpat® is made by the physician)

• Patient must be at least 18 years of age

• The patient must have had at least one seizure within the last 3 months prior to enrolment